Induction chemotherapy with albumin-bound paclitaxel plus lobaplatin followed by concurrent radiochemotherapy for locally advanced esophageal cancer

Yan, Mao-Hui; Liu, Fang; Qu, Baolin; Cai, Baiqiang; Wang, Yu; Dai, X.

doi:10.4251/wjgo.v13.i11.1781

Cited by 4 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The combination pattern showed significant improvements in OS, PFS, and ORRs. In a previous study, we found that nab-paclitaxel was effective in patients with locally advanced ESCC, with mild adverse effects (23). Therefore, different from the chemotherapy regimen of 5-fluorouracil plus cisplatin in the KEYNOTE-590 trial, we used the nab-paclitaxel plus platinum regimen in the current study.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of combined treatment with pembrolizumab in patients with locally advanced or metastatic esophageal squamous cell carcinoma in the real world

Zhang¹,

Hou²,

Cai³

et al. 2022

Ann Transl Med

Self Cite

View full text Add to dashboard Cite

Background: Treatments for patients with advanced esophageal cancer are still limited. Pembrolizumab has demonstrated antitumor activity in patients with advanced esophageal cancer in previous studies. Few studies have assessed safety and efficacy in routine clinical practice. We investigated the real-world outcomes of pembrolizumab for patients with advanced esophageal cancer.Methods: This retrospective, observational study collected 57 advanced esophageal squamous cell carcinoma (ESCC) patients from October 1, 2019 to October 1, 2021, 57 who received different patterns of treatments according to the staging were collected. Briefly, patients diagnosed with locally advanced and surgically resectable ESCC received neoadjuvant therapy followed by surgery. For patients with locally advanced, unresectable ESCC, the treatment regimen including chemoradiotherapy combined with pembrolizumab was performed. Patients with metastatic ESCC or those not suitable for radiotherapy received pembrolizumab plus chemotherapy. Safety was assessed in all treated patients. The objective response rate (ORR) was used to evaluate the efficacy. Results:The ORR was 74.1% (40/54) among all patients. The most common adverse events (AEs) were leukopenia (36.8%, 21/57), nausea (28.1%, 16/57), and thrombocytopenia (14%, 8/57). Grade III and higher AEs were observed in 9 of the 57 patients (15.8%).Conclusions: For patients with advanced ESCC, combined treatment with pembrolizumab was effective and safe. Multicenter studies should be carried out for further confirmation.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of combined treatment with pembrolizumab in patients with locally advanced or metastatic esophageal squamous cell carcinoma in the real world

Zhang¹,

Hou²,

Cai³

et al. 2022

Ann Transl Med

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, we did not observe the advantage of IC in large tumors. The chemotherapy sensitivity of ESCC was poor, and the effective rate of first-line chemotherapy was generally 30-58% ( 11 – 13 ). In the Norton-Simon model ( 14 ), gmopertzian growth curve showed that the tumor growth rate will gradually slow down with the growth of the tumor volume, and the chemotherapy efficacy was positively correlated with the tumor growth rate.…”

Section: Discussionmentioning

confidence: 99%

Induction chemotherapy increases efficacy and survival rate of patients with locally advanced esophageal squamous cell carcinoma

et al. 2022

View full text Add to dashboard Cite

ObjectiveThe efficacy of concurrent chemoradiotherapy (CRT) after induction chemotherapy (IC) in the treatment of esophageal squamous cell carcinoma (ESCC) remains unclear. The purpose of this study was to explore the efficacy of IC in patients with ESCC.Methods124 patients with ESCC receiving CRT were included. Patients were divided into IC+CRT group and CRT group. Short-term and long-term efficacy as well as survival time of the two groups were compared, influencing factors of IC efficacy were investigated, and overall survival (OS) and progression-free survival (PFS) between the two groups were compared in different subgroups.ResultsThere was no significant difference in the objective response rate (ORR) between the two groups. After IC, the ORR was higher in patients with single-drug concurrent chemotherapy weekly and patients with effective IC. In the long-term efficacy, advanced clinical stage patients had a shorter PFS compared to early-stage patients, and chemoradiotherapy mode ameliorates patients’ PFS. OS and PFS of IC+CRT group were longer than that of CRT group in both tumor diameter <5cm and single-drug chemotherapy weekly subgroups. In addition, OS of IC+CRT group was longer than that of CRT group in pathological grade G1-2 subgroup.ConclusionsIC improve the efficacy and survival rate of patients with locally advanced ESCC, and the benefits are more advantageous in subgroups of effective IC, pathological grade G1-2, tumor diameter < 5cm, single-drug concurrent chemotherapy weekly.

show abstract

Simultaneous determination of paclitaxel and vinorelbine from environmental water and urine samples based on dispersive micro solid phase extraction-HPLC using a green and novel MOF-On-MOF sorbent composite

Abad

Masrournia

Javid

2023

Microchemical Journal

View full text Add to dashboard Cite

Induction chemotherapy with albumin-bound paclitaxel plus lobaplatin followed by concurrent radiochemotherapy for locally advanced esophageal cancer

Cited by 4 publications

References 20 publications

Efficacy and safety of combined treatment with pembrolizumab in patients with locally advanced or metastatic esophageal squamous cell carcinoma in the real world

Efficacy and safety of combined treatment with pembrolizumab in patients with locally advanced or metastatic esophageal squamous cell carcinoma in the real world

Induction chemotherapy increases efficacy and survival rate of patients with locally advanced esophageal squamous cell carcinoma

Simultaneous determination of paclitaxel and vinorelbine from environmental water and urine samples based on dispersive micro solid phase extraction-HPLC using a green and novel MOF-On-MOF sorbent composite

Contact Info

Product

Resources

About